- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03813836
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)
A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Emily Ambrose
- Phone Number: 020 7679 9483
- Email: ctc.poppy@ucl.ac.uk
Study Contact Backup
- Name: Rubina Begum
- Phone Number: 020 7679 9514
- Email: ctc.poppy@ucl.ac.uk
Study Locations
-
-
-
Aberdeen, United Kingdom
- Recruiting
- Aberdeen Royal Infirmary (NHS Grampian)
-
Bristol, United Kingdom
- Recruiting
- Bristol Haematology and Oncology Centre (University Hospital Bristol NHS Foundation Trust)
-
Edinburgh, United Kingdom
- Recruiting
- Western General Hospital (NHS Lothian)
-
Ipswich, United Kingdom
- Recruiting
- East Suffolk and North Essex NHS Foundation Trust
-
London, United Kingdom
- Recruiting
- University College London Hospital
-
London, United Kingdom
- Recruiting
- Guy's and St Thomas' NHS Foundation Trust
-
Manchester, United Kingdom
- Recruiting
- The Christie NHS Foundation Trust
-
Northwood, United Kingdom
- Recruiting
- East and North Hertfordshire NHS Trust
-
Romford, United Kingdom
- Recruiting
- Queens Hospital (Barking, Havering and Redbridge University Hospitals NHS Trust)
-
Taunton, United Kingdom
- Recruiting
- Musgrove Park Hospital (Somerset NHS Foundation Trust)
-
Truro, United Kingdom
- Recruiting
- Royal Cornwall Hospital Trust
-
Wirral, United Kingdom
- Recruiting
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies.
- Measurable disease evaluated by RECIST v1.1
- WHO performance status of 2
- Life expectancy of at least 12 weeks
- Aged ≥ 18 years of age
Adequate Bone marrow function:
- Absolute neutrophils grade 0 or 1 (using CTCAE v5)
- Platelets grade 0 or 1
- Haemoglobin grade 0 or 1
Adequate renal function:
Creatinine grade 0 or 1 Calculated glomerular filtration rate (GFR) ≥ 50 mL/min estimated using validated creatinine clearance calculation (e.g. Cockcroft-Gault or Wright formula). If calculated GFR is < 50 mL/min then an isotope GFR assessment (Cr51-EDTA or 99mTc-DTPA) should be performed. If an isotope GFR test is unavailable an estimation from 24 hour urine collection may be used
Adequate liver function:
Serum bilirubin grade 0 or 1 AST and ALT grade 0 or 1 (up to grade 2 for patients with liver metastases)
- Willing to use contraception for the duration of trial treatment and for 120 days after completion of treatment
- Willing to have a new biopsy, if site of disease is accessible and considered safe to biopsy by investigator If newly obtained samples cannot be obtained (e.g. inaccessible disease or patient safety concern) sites may submit archival tissue only upon agreement from the sponsor
- Able to give informed consent, indicating that the patient has been informed of and understands the experimental nature of the study, possible risks and benefits, trial procedures, and alternative options
- Willing and able to comply with the protocol for the duration of the study, including the treatment plan, investigations required and follow up visits
Exclusion Criteria:
- Patients with undifferentiated nasopharyngeal or sino-nasal cancers
- Disease suitable for treatment with curative intent
- Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent
- Any investigational agents within 4 weeks prior to registration
- Anti-cancer monoclonal antibody therapy within 4 weeks prior to registration
- Chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to registration
- Patients with concurrent or previous malignancy that could compromise assessment of the primary or secondary endpoints of the trial
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
- Grade 3 or 4 peripheral neuropathy
- Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinician's judgment, could interfere with patient safety or obtaining informed consent
Active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they:
Are stable, without evidence of progression for at least four weeks prior to the first dose of trial treatment Have no evidence of new or enlarging brain metastases Have no evidence of leptomeningeal disease Are not using steroids for at least 7 days prior to trial treatment
- Has a known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (hepatitis C virus [HCV] RNA [qualitative] is detected) NB: Without known history, testing is required to determine eligibility. Hepatitis C antibody testing is allowed for screening purposes in sites where HCV RNA is not part of standard of care
- Immunocompromised patients (e.g. known HIV positive status)*
- Prior organ transplantation including allogenic stem-cell transplantation
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids, or current pneumonitis/interstitial lung disease
- Active infection requiring systemic therapy
- Has received a live vaccine within 30 days prior to registration (seasonal flu vaccines that do not contain live virus are permitted)
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (NB: the use of physiologic doses of corticosteroids may be approved after consultation with UCL CTC)
Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent. Patients with the following are eligible:
Autoimmune-related hyperthyroidism or autoimmune-related hypothyroidism who are in remission or on a stable dose of thyroid-replacement hormone Vitiligo Psoriasis
- Current use of immunosuppressive medication, except for the following:
intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisolone or equivalent (after approval by UCL CTC) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
*Testing for HIV for the POPPY trial is not mandatory, however if this test has been done the result should be known prior to registration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pembrolizumab + best supportive care
Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
|
Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate at 24 weeks assessed using iRECIST
Time Frame: 24 weeks after registration
|
Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST
|
24 weeks after registration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate assessed using iRECIST
Time Frame: 12 months after registration
|
Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST
|
12 months after registration
|
Best Response Rate- measured using the change from baseline tumour size. Assessed using iRECIST.
Time Frame: 6 months after registration
|
Best Response Rate, defined as proportion of patients who have a CR or PR as their best response, measured using the change from baseline tumour size, assessed using iRECIST
|
6 months after registration
|
Clinical Benefit Rate -defined as patient's best response rate lasting at least 18 weeks
Time Frame: From start of treatment to 30 months post start of treatment
|
Clinical Benefit Rate, defined as proportion patients who have achieved CR, PR or SD as their best response lasting at least 18 weeks
|
From start of treatment to 30 months post start of treatment
|
Duration of Response- defined as the time from first documented evidence of CR or PR until disease progression or death.
Time Frame: From start of treatment to 30 months post start of treatment
|
Duration of Response, defined as the time from first documented evidence of CR or PR until disease progression or death
|
From start of treatment to 30 months post start of treatment
|
Time to Progression -defined as time from registration to the first documented disease progression
Time Frame: From registration to 30 months post start of treatment
|
Time to Progression, defined as time from registration to the first documented disease progression
|
From registration to 30 months post start of treatment
|
Progression Free Survival defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first.
Time Frame: From registration to 30 months post start of treatment
|
Progression Free Survival, defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first.
|
From registration to 30 months post start of treatment
|
Overall Survival- defined as the time from registration to death due to any cause.
Time Frame: From registration to 30 months post start of treatment
|
Overall Survival, defined as the time from registration to death due to any cause.
|
From registration to 30 months post start of treatment
|
Frequency and severity of adverse events- throughout the patient's treatment and until 6 months after completion of trial treatment.
Time Frame: From date of registration until 6 months after completion of trial treatment
|
Frequency and severity of adverse events
|
From date of registration until 6 months after completion of trial treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Martin Forster, FRCP PhD, University College, London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Recurrence
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- UCL/17/0396
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Squamous Cell Carcinoma
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Glenn J. HannaImmunityBio, Inc.RecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Washington University School of MedicineEli Lilly and CompanyRecruitingRecurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Shyam S.D. RaoNational Cancer Institute (NCI)RecruitingMetastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell CarcinomaUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); AstraZenecaTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaUnited States
-
Novartis PharmaceuticalsTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaFrance, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
-
Washington University School of MedicineMerck Sharp & Dohme LLC; Joseph Sanchez FoundationActive, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaUnited States
Clinical Trials on Pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States